Characterization of protein unable to bind von Willebrand factor in recombinant factor VIII products

• Published in: Journal of thrombosis and haemostasis Vol. 19; no. 4; pp. 954 - 966
• Main Authors: Chun, Haarin, Pettersson, John R., Shestopal, Svetlana A., Wu, Wells W., Marakasova, Ekaterina S., Olivares, Philip, Surov, Stepan S., Ovanesov, Mikhail V., Shen, Rong‐Fong, Sarafanov, Andrey G.
• Format: Journal Article
• Language: English
• Published: England Elsevier Limited 01.04.2021
• Subjects: affinity; Affinity chromatography; Animals; Blood Coagulation Tests; chromatography; Coagulation factor VIII; Coagulation factors; Factor VIII; Gel electrophoresis; Hemophilia; hemophilia A; Hemophilia A - drug therapy; Hemostatics; Immunoblotting; low density lipoprotein receptor‐related protein‐1; Mass spectroscopy; Mice; Protein structure; Proteins; Receptor density; Surface plasmon resonance; Von Willebrand factor; hemophilia A; low density lipoprotein receptor-related protein-1; von Willebrand Factor; factor VIII; chromatography; affinity
• ISSN: 1538-7933; 1538-7836; 1538-7836
• DOI: 10.1111/jth.15257

Background Therapeutic products with coagulation factor VIII (FVIII) have a wide range of specific activities, implying presence of protein with altered structure. Previous studies showed that recombinant FVIII products (rFVIII) contain a fraction (FVIIIFT) unable to bind von Willebrand factor (VWF) and reported to lack activity. Because of loss of function(s), FVIIIFT can be defined as a product‐related impurity, whose properties and levels in rFVIII products should be investigated. Objective To isolate and characterize the FVIIIFT fraction in rFVIII products. Methods Protein fractions unable (FVIIIFT) and able (FVIIIEL) to bind VWF were isolated from rFVIII products using immobilized VWF affinity chromatography (IVAC) and characterized by gel electrophoresis, immunoblotting, FVIII activity test, surface plasmon resonance, mass spectrometry, and for plasma clearance in mice. Results and Conclusions A robust IVAC methodology was developed and applied for analysis of 10 rFVIII products marketed in the United States. FVIIIFT was found at various contents (0.4%‐21.5%) in all products. Compared with FVIIIEL, FVIIIFT had similar patterns of polypeptide bands by gel electrophoresis, but lower functional activity. In several representative products, FVIIIFT was found to have reduced sulfation at Tyr1680, important for VWF binding, decreased interaction with a low‐density lipoprotein receptor‐related protein 1 fragment, and faster plasma clearance in mice. These findings provide basic characterization of FVIIIFT and demonstrate a potential for IVAC to control this impurity in rFVIII products to improve their efficacy in therapy of hemophilia A.